TOWARDS A VACCINE TO PREVENT TOXOPLASMOSIS
2010 Annual Report
1a.Objectives (from AD-416)
Develop an integrated risk model for toxoplasma in the U.S. pork industry.
1b.Approach (from AD-416)
Will test various drug or vaccine candidates in mice experimentally-infected with Toxoplasma strains of different genotypes.
This is a multi-institutional five year agreement funded through National Institutes of Health. The main objective is to develop a protective vaccine for Toxoplasma. The infectivity and pathogenicity of three typical genotypes of Toxoplasma gondii (Types III, II, and I) and five atypical oocysts were compared in 4 strains of mice, Swiss Webster outbred mice, BALB/c inbred mice, HLA3.11 and HLA 2.1.; Only minor differences were found with respect to strain of the mouse. Oocysts of the Type I strain were lethal to all strains of mice. This information will be used to test protection in mice immunized with different vaccine candidates. Project plans, goals, and accomplishments were discussed via conference calls and e-mail; technical advice was provided to the Cooperator in writing and by teleconference.